NEW YORK, June 28, 2016 /PRNewswire/ -- Attorney
Advertising -- Bronstein, Gewirtz & Grossman, LLC is
investigating potential claims on behalf of purchasers of the
securities of Regulus Therapeutics Inc. ("Regulus" or the
"Company") (NASDAQ: RGLS). Such investors are advised to contact
Peretz Bronstein or his investor
relations analyst, Yael Hurwitz at
info@bgandg.com or 212-697-6484.
The investigation concerns whether Regulus and certain of its
officers and/or directors have violated Sections 10(b) and 20(a) of
the Securities Exchange Act of 1934.
On June 27, 2016, Regulus released
that it had received notice from the U.S. Food and Drug
Administration ("FDA") that its new drug for the treatment of
chronic hepatitis C virus infection which was under FDA review, is
now being put on clinical hold after a second serious case of
jaundice was reported. Following this news, Regulus dropped
$2.71 per share, or over 54%, to
$2.30 after-market hours on
June 27, 2016.
If you purchased Regulus or if you are aware of any facts
relating to this investigation, you can assist this investigation
by visiting the firm's site: http://www.bgandg.com/#!rgls/ibb0q.
You can also contact Peretz
Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz &
Grossman, LLC: 212-697-6484 or via email info@bgandg.com. Those who
inquire by e-mail are encouraged to include their mailing address,
email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation
boutique. Our primary expertise is the aggressive pursuit of
litigation claims on behalf of our clients. In addition to
representing institutions and other investor plaintiffs in class
action security litigation, the firm's expertise includes general
corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not
guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-regulus-therapeutics-inc-rgls-300291293.html
SOURCE Bronstein, Gewirtz & Grossman, LLC